Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | JAK3 | P52333 | 4/20 | 0.51 |
| ▸ | AURKA | O14965 | 1/20 | 0.51 |
| ▸ | EGFR | P00533 | 1/20 | 0.51 |
| ▸ | NTRK1 | P04629 | 1/20 | 0.51 |
| ▸ | CDK1 | P06493 | 1/20 | 0.51 |
| ▸ | IGF1R | P08069 | 1/20 | 0.51 |
| ▸ | KIT | P10721 | 1/20 | 0.51 |
| ▸ | EPHA1 | P21709 | 1/20 | 0.51 |
| ▸ | CDK2 | P24941 | 1/20 | 0.51 |
| ▸ | FLT3 | P36888 | 1/20 | 0.51 |
| ▸ | BMX | P51813 | 1/20 | 0.51 |
| ▸ | CDK6 | Q00534 | 1/20 | 0.51 |
| ▸ | PAK1 | Q13153 | 1/20 | 0.51 |
| ▸ | ALK | Q9UM73 | 1/20 | 0.51 |
| ▸ | JAK2 | O60674 | 11/20 | 0.49 |
| ▸ | JAK1 | P23458 | 11/20 | 0.49 |
| ▸ | SYK | P43405 | 2/20 | 0.49 |
| ▸ | PTK2 | Q05397 | 3/20 | 0.49 |
| ▸ | LCK | P06239 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12438378 | 0.90 | JAK3 (0.52) | JAK3AURKAEGFRNTRK1CDK1 | |
| SCHEMBL10148425 | 0.89 | JAK3 (0.54) | JAK3AURKAEGFRNTRK1CDK1 | |
| SCHEMBL10149268 | 0.87 | SYK (0.52) | JAK3JAK2JAK1SYKPTK2 | |
| SCHEMBL2324528 | 0.87 | JAK2 (0.51) | AURKAIGF1RJAK2JAK1SYK | |
| Bicarbonate SCHEMBL579108 | 0.83 | FLT3 (0.64) | JAK3AURKAEGFRNTRK1CDK1 | |
| Bicarbonate SCHEMBL579262 | 0.83 | KIT (0.64) | JAK3AURKAEGFRNTRK1CDK1 | |
| SCHEMBL13808086 | 0.83 | FLT3 (0.61) | JAK3AURKAEGFRNTRK1CDK1 | |
| SCHEMBL579261 | 0.83 | FLT3 (0.61) | JAK3AURKAEGFRNTRK1CDK1 | |
| SCHEMBL578790 | 0.82 | FLT3 (0.55) | JAK3AURKAEGFRNTRK1CDK1 | |
| SCHEMBL13808085 | 0.82 | FLT3 (0.55) | JAK3AURKAEGFRNTRK1CDK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8623887-B2 | Compounds | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2014-01-07 | — | — | US | disclosed |
| US-8623887-B2 | Compounds | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2014-01-07 | — | — | US | disclosed |
| US-8623887-B2 | Compounds | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2014-01-07 | — | — | US | disclosed |
| US-20130281429-A1 | 2,4-DIAMINO-PYRIMIDINES AS AURORA INHIBITORS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2013-10-24 | — | — | US | disclosed |
| US-20130281429-A1 | 2,4-DIAMINO-PYRIMIDINES AS AURORA INHIBITORS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2013-10-24 | — | — | US | disclosed |
| US-20130281429-A1 | 2,4-DIAMINO-PYRIMIDINES AS AURORA INHIBITORS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2013-10-24 | — | — | US | disclosed |
| EP-2027107-B1 | 2, 4 -DIAMINO PYRIMIDINES AS CELL CYCLE KINASE INHIBITORS | BOEHRINGER INGELHEIM INT (DE) | 2012-02-15 | — | — | EP | disclosed |
| US-20110251174-A1 | 2,4-DIAMINO-PYRIMIDINES AS AURORA INHIBITORS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2011-10-13 | — | — | US | disclosed |
| US-20110251174-A1 | 2,4-DIAMINO-PYRIMIDINES AS AURORA INHIBITORS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2011-10-13 | — | — | US | disclosed |
| US-20110251174-A1 | 2,4-DIAMINO-PYRIMIDINES AS AURORA INHIBITORS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2011-10-13 | — | — | US | disclosed |
| US-20090163467-A1 | New compounds | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2009-06-25 | — | — | US | disclosed |
| US-20090163467-A1 | New compounds | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2009-06-25 | — | — | US | disclosed |
| US-20090163467-A1 | New compounds | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2009-06-25 | — | — | US | disclosed |
| CN-101443325-A | 2, 4 -diamino pyrimidines as cell cycle kinase inhibitors | SANOFI AVENTIS DEUTSCHLAND (DE) | 2009-05-27 | — | — | CN | disclosed |
| CN-101213179-A | 2, 4-diamino-pyrimidines as Aurora inhibitors | BOEHRINGER INGELHEIM INT (DE) | 2008-07-02 | — | — | CN | disclosed |
| WO-2007132010-A1 | 2, 4 -DIAMINO PYRIMIDINES AS CELL CYCLE KINASE INHIBITORS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2007-11-22 | — | — | WO | disclosed |
| US-20070032514-A1 | 2,4-diamino-pyrimidines as aurora inhibitors | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2007-02-08 | — | — | US | disclosed |
| US-20070032514-A1 | 2,4-diamino-pyrimidines as aurora inhibitors | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2007-02-08 | — | — | US | disclosed |
| US-20070032514-A1 | 2,4-diamino-pyrimidines as aurora inhibitors | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2007-02-08 | — | — | US | disclosed |
| WO-2007003596-A1 | 2,4-DIAMINO-PYRIMIDINES USED AS AURORA INHIBITORS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2007-01-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110251174-A1 | 2,4-DIAMINO-PYRIMIDINES AS AURORA INHIBITORS | AURKA, AURKC, AURKB | JAK3 811/4885AURKA 1/4885EGFR 289/4885 |
| US-20070032514-A1 | 2,4-diamino-pyrimidines as aurora inhibitors | AURKA, AURKC, AURKB | JAK3 811/4885AURKA 1/4885EGFR 289/4885 |
| US-20130281429-A1 | 2,4-DIAMINO-PYRIMIDINES AS AURORA INHIBITORS | AURKA, AURKC, AURKB | JAK3 811/4885AURKA 1/4885EGFR 289/4885 |
| US-20090163467-A1 | New compounds | CCNA1, MKI67, CCNT1 | JAK3 3295/4885AURKA 2076/4885EGFR 409/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.